Schirinzi Tommaso, Maftei Daniela, Passali Francesco M, Grillo Piergiorgio, Zenuni Henri, Mascioli Davide, Maurizi Riccardo, Loccisano Laura, Vincenzi Martina, Rinaldi Anna Maria, Ralli Massimo, Di Girolamo Stefano, Stefani Alessandro, Lattanzi Roberta, Severini Cinzia, Mercuri Nicola B
Unit of Neurology, Department of Systems Medicine, Tor Vergata University of Rome, Rome, Italy.
Department of Physiology and Pharmacology "V. Erspamer,", Sapienza University of Rome, Rome, Italy.
Ann Neurol. 2023 Jan;93(1):196-204. doi: 10.1002/ana.26526. Epub 2022 Oct 26.
The objective of this study was to outline the dynamics of prokineticin-2 pathway in relation to clinical-pathological features of Parkinson's disease by examining olfactory neurons of patients.
Thirty-eight patients (26 de novo, newly diagnosed) and 31 sex/age-matched healthy controls underwent noninvasive mucosa brushing for olfactory neurons collection, and standard clinical assessment. Gene expression levels of prokineticin-2, prokineticin-2 receptors type 1 and 2, and prokineticin-2-long peptide were measured in olfactory neurons by real-time polymerase chain reaction (PCR); moreover, the prokineticin-2 protein and α-synuclein species (total and oligomeric) were quantified by immunofluorescence staining.
Prokineticin-2 expression was significantly increased in Parkinson's disease. De novo patients had higher prokineticin-2 levels, directly correlated with Movement Disorder Society-Sponsored Revision of the Unified Parkinson Disease Rating Scale (MDS-UPDRS) part III motor score. In addition, oligomeric α-synuclein was higher in Parkinson's disease and directly correlated with prokineticin-2 protein levels. Total α-synuclein did not differ between patients and controls.
Prokineticin-2 is a chemokine showing neuroprotective effects in experimental models of Parkinson's disease, but translational proof of its role in patients is still lacking. Here, we used olfactory neurons as the ideal tissue to analyze molecular stages of neurodegeneration in vivo, providing unprecedented evidence that the prokineticin-2 pathway is activated in patients with Parkinson's disease. Specifically, prokineticin-2 expression in olfactory neurons was higher at early disease stages, proportional to motor severity, and associated with oligomeric α-synuclein accumulation. These data, consistently with preclinical findings, support prokineticin-2 as a candidate target in Parkinson's disease, and validate reliability of olfactory neurons to reflect pathological changes of the disease. ANN NEUROL 2023;93:196-204.
本研究的目的是通过检查帕金森病患者的嗅觉神经元,概述促动力蛋白-2通路与帕金森病临床病理特征相关的动态变化。
38例患者(26例初发、新诊断患者)和31例性别/年龄匹配的健康对照者接受了无创黏膜刷取以收集嗅觉神经元,并进行了标准的临床评估。通过实时聚合酶链反应(PCR)测量嗅觉神经元中促动力蛋白-2、促动力蛋白-2受体1型和2型以及促动力蛋白-2长肽的基因表达水平;此外,通过免疫荧光染色对促动力蛋白-2蛋白和α-突触核蛋白种类(总蛋白和寡聚体)进行定量。
帕金森病患者中促动力蛋白-2表达显著增加。初发患者促动力蛋白-2水平更高,与运动障碍协会赞助的统一帕金森病评定量表(MDS-UPDRS)第三部分运动评分直接相关。此外,帕金森病患者中寡聚体α-突触核蛋白更高,且与促动力蛋白-2蛋白水平直接相关。患者和对照者之间总α-突触核蛋白无差异。
促动力蛋白-2是一种趋化因子,在帕金森病实验模型中显示出神经保护作用,但仍缺乏其在患者中作用的转化证据。在此,我们将嗅觉神经元用作分析体内神经退行性变分子阶段的理想组织,提供了前所未有的证据表明帕金森病患者中促动力蛋白-2通路被激活。具体而言,嗅觉神经元中促动力蛋白-2表达在疾病早期更高,与运动严重程度成正比,并与寡聚体α-突触核蛋白积累相关。这些数据与临床前研究结果一致,支持促动力蛋白-2作为帕金森病的候选靶点,并验证了嗅觉神经元反映疾病病理变化的可靠性。《神经病学年鉴》2023年;93卷:196 - 204页